Evidence map›Paper›PMID 39434125›Full record

ArticleMolecular neurodegeneration2024

Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease.

Xavier Taylor, Harun N Noristani, Griffin J Fitzgerald, Herold Oluoch, Nick Babb, Tyler McGathey, Lindsay Carter, Justin T Hole, Pascale N Lacor, Ronald B DeMattos and 1 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. The spleen-brain axis in Alzheimer's disease and related dementias: Integrating immune and metabolic regulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Pediatric discovery · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xavier TaylorLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA. taylor_xavier@lilly.com.
Harun N NoristaniLilly Research Laboratories, Imaging Research and Development, Eli Lilly and Company, Philadelphia, PA, 19107, USA.
Griffin J FitzgeraldLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Herold OluochLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Nick BabbLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Tyler McGatheyLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Lindsay CarterLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Justin T HoleLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Pascale N LacorLilly Research Laboratories, Imaging Research and Development, Eli Lilly and Company, Philadelphia, PA, 19107, USA.
Ronald B DeMattosLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA.
Yaming WangLilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, 46225, IN, USA. wang_yaming@lilly.com.ORCID 0000-0003-4973-3291

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-amyloid-β (Aβ) immunotherapy trials have revealed amyloid-related imaging abnormalities (ARIA) as the most prevalent and serious adverse events linked to pathological changes in cerebral vasculature. Recent studies underscore the critical involvement of perivascular macrophages and the infiltration of peripheral immune cells in regulating cerebrovascular damage. Specifically, Aβ antibodies engaged at cerebral amyloid angiopathy (CAA) deposits trigger perivascular macrophage activation and the upregulation of genes associated with vascular permeability. Nevertheless, further research is needed to understand the immediate downstream consequences of macrophage activation, potentially exacerbating CAA-related vascular permeability and microhemorrhages linked to Aβ immunotherapy.

methodsThis study investigates immune responses induced by amyloid-targeting antibodies and CAA-induced microhemorrhages using RNA in situ hybridization, histology and digital spatial profiling in an Alzheimer's disease (AD) mouse model of microhemorrhage.

resultsIn the present study, we have demonstrated that bapineuzumab murine surrogate (3D6) induces profound vascular damage, leading to smooth muscle cell loss and blood-brain barrier (BBB) breakdown. In addition, digital spatial profiling (DSP) reveals that distinct immune responses contribute to vascular damage with peripheral immune responses and perivascular macrophage activation linked to smooth muscle cell loss and vascular fibrosis, respectively. Finally, RNA in situ hybridization identifies two distinct subsets of Trem2

conclusionsIn summary, our study has established a significant link between CAA-Aβ antibody immune complex formation, immune activation and vascular damage leading to smooth muscle cell loss. However, the full implications of this cascade on the development of microhemorrhages requires further exploration. Additional investigations are warranted to unravel the precise molecular mechanisms leading to microhemorrhage, the interplay of diverse immune populations and the functional roles played by various Trem2

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCerebral Amyloid AngiopathyImmunotherapyAnimalsAntibodies, Monoclonal, HumanizedBlood-Brain BarrierCerebral HemorrhageDisease Models, AnimalHumansInflammationMiceMice, TransgenicAmyloid beta-PeptidesAntibodies, Monoclonal, Humanizedbapineuzumab

Identifiers

PMID39434125
PMCPMC11494988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.